BTK and neoplasm: This review article focuses on three main aspects: (1) discuss the current BTKis approved for clinical use in the USA, (2) detail the various mechanisms of BTK resistance including the role of genetic alteration, cancer stem cells, tumor microenvironment, and adaptive reprogramming bypassing the effect of BTK inhibition, and (3) current and emerging therapeutic strategies beyond BTKi.